Table 2. (Continued)  

| Cell line     | α   | βI/βII | γ   | δ   | ε   | η   | θ   | ζ   | λ/i | Detection * | Reference |
|---------------|-----|--------|-----|-----|-----|-----|-----|-----|-----|-------------|-----------|
| WM115 (primary) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [36]      |
| WM120S (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [36]      |
| SK-Mel 28 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W, R        | [29]      |
| A375 (primary)  | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W, R        | [29]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [37]      |
| B16F1 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [38]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [39]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [40]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [41]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [42]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [43]      |
| B16 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [44]      |
| B16-1BL6 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [45]      |
| B16-1BL6 (metastatic) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | W           | [46]      |

* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction.
** Not determined.

the β isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo [50]. It is interesting to assume that the β isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC β isoform [25,27]. On the other hand, the α isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this PKC isoform enhances the melanin synthesis, suggesting the involvement of the α isoform in melanogenesis [38]. The level of the α isoform is also elevated in B16 cells cultured with mannosylerythritol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL-60 promyelocytic leukemia cells [44]. The introduction of antisense oligodeoxynucleotides against the α isoform prevented mannosylerythritol lipid-induced melanogenesis, and the expression of the

Table 3. The expression of PKC isoforms in human melanoma cells in vivo

| Origin     | Clinical type* | α   | βI/βII | γ   | δ   | ε   | η   | θ   | ζ   | λ/i | Detection** | Reference |
|------------|----------------|-----|--------|-----|-----|-----|-----|-----|-----|-----|-------------|-----------|
| Primary    | ALM            | +   | −      | −   | +   | +   | ND***| ND  | ND  | ND  | W           | [25]      |
| Metastatic | Unknown        | +   | −      | −   | +   | +   | ND  | ND  | ND  | ND  | W           | [25]      |
| Metastatic | NS (5 cases)   | ND  | +      | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [27]      |
| Metastatic | NS (5 cases)   | ND  | −      | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [27]      |
| Metastatic | SSM            | +   | +      | −   | +   | +   | −   | +   | +   | W           | [28]      |
| Metastatic | NS (5 cases)   | +   | +      | −   | +   | +   | −   | +   | +   | W           | [28]      |
| Metastatic | ALM (2 cases)  | +   | +      | −   | +   | +   | −   | +   | +   | W           | [28]      |
| Primary    | ALM            | −   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [36]      |
| Primary    | ALM (11 cases) | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [36]      |
| Primary    | SSM (7 cases)  | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [36]      |
| Metastatic | ALM (2 cases)  | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [36]      |
| Metastatic | SSM (2 cases)  | +   | ND     | ND  | ND  | ND  | ND  | ND  | ND  | ND  | I           | [36]      |

* ALM: acral lentigious melanoma; SSM: superficial spreading melanoma, NS: not stated.
** W: Western blot, I: immunohistochemistry.
*** Not determined.